Cargando…
Efficacy and Outcomes of CYP3A5 Genotype-Based Tacrolimus Dosing Compared to Conventional Body Weight-based Dosing in Living Donor Kidney Transplant Recipients
INTRODUCTION: Clinical use of tacrolimus has been challenging due to its narrow therapeutic index and highly variable pharmacokinetics. In this study, we compared patients who received body weight-based tacrolimus dosing pre-transplant (transplanted from 2016 to 2018) with those who received CYP3A5...
Autores principales: | Raj, T. Yashwanth, Fernando, M. Edwin, Srinivasa Prasad, N. D., Sujit, S., Valavan, K. Thirumal, Harshavardhan, T. S., Ramanathan, Arvind |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9267083/ https://www.ncbi.nlm.nih.gov/pubmed/35814319 http://dx.doi.org/10.4103/ijn.IJN_278_20 |
Ejemplares similares
-
Influence of CYP3A5 and ABCB1 Polymorphism on Tacrolimus Drug Dosing in South Indian Renal Allograft Recipients
por: Fernando, M. Edwin, et al.
Publicado: (2019) -
Membranous Nephropathy with Rapid Progression
por: Vairakkani, R., et al.
Publicado: (2020) -
Differences in CYP3A genotypes of a liver transplant recipient and the donor liver graft and adjustment of tacrolimus dose
por: Berger, Florine A., et al.
Publicado: (2019) -
Pharmacogenetics Based Dose Prediction Model for Initial Tacrolimus Dosing in Renal Transplant Recipients
por: Srinivas, Lekshmy, et al.
Publicado: (2021) -
CYP3A-status is associated with blood concentration and dose-requirement of tacrolimus in heart transplant recipients
por: Déri, Máté, et al.
Publicado: (2021)